One hundred forty-eight patients with advanced CRC previously treated with fluoropyrimidine or irinotecan received bevacizumab ( 10 mg/kg , intravenous ) , low-dose linifanib ( 7.5 mg ) , or high-dose linifanib ( 12.5 mg ) , with mFOLFOX6 .